Chiara Chiozzini

List of Publications by Year
in descending order

49	1,645	279798	302126
papers	citations	23 h-index	39 g-index

53	53	53	1979
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell, 2003, 3, 131-143.	16.8	221
2	In Vivo-Restricted and Reversible Malignancy Induced by Human Herpesvirus-8 KSHV: A Cell and Animal Model of Virally Induced Kaposi's Sarcoma. Cancer Cell, 2007, 11, 245-258.	16.8	148
3	Exosomes from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Cells License Quiescent CD4 ⁺ T Lymphocytes To Replicate HIV-1 through a Nef- and ADAM17-Dependent Mechanism. Journal of Virology, 2014, 88, 11529-11539.	3.4	140
4	Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1. Retrovirology, 2015, 12, 87.	2.0	77
5	An Exosomeâ€Based Vaccine Platform Imparts Cytotoxic T Lymphocyte Immunity Against Viral Antigens. Biotechnology Journal, 2018, 13, e1700443.	3.5	77
6	Alpha Interferon Inhibits Human Herpesvirus 8 (HHV-8) Reactivation in Primary Effusion Lymphoma Cells and Reduces HHV-8 Load in Cultured Peripheral Blood Mononuclear Cells. Journal of Virology, 1999, 73, 4029-4041.	3.4	70
7	HIV-1 Tat Regulates Endothelial Cell Cycle Progression via Activation of the Ras/ERK MAPK Signaling Pathway. Molecular Biology of the Cell, 2006, 17, 1985-1994.	2.1	66
8	Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation. International Journal of Nanomedicine, 2017, Volume 12, 4579-4591.	6.7	58
9	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. PLoS ONE, 2012, 7, e48781.	2.5	56
10	A Role for Virally Induced Reactive Oxygen Species in Kaposi's Sarcoma Herpesvirus Tumorigenesis. Antioxidants and Redox Signaling, 2013, 18, 80-90.	5.4	54
11	Cell activation and HIV-1 replication in unstimulated CD4+T lymphocytes ingesting exosomes from cells expressing defective HIV-1. Retrovirology, 2014, 11, 46.	2.0	52
12	HPV-E7 Delivered by Engineered Exosomes Elicits a Protective CD8+ T Cell-Mediated Immune Response. Viruses, 2015, 7, 1079-1099.	3.3	47
13	Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasomeâ€independent block of angiogenesis and matrix metalloproteinases. International Journal of Cancer, 2011, 128, 82-93.	5.1	40
14	Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology, 2009, 395, 45-55.	2.4	39
15	Exosomes in Therapy: Engineering, Pharmacokinetics and Future Applications. Current Drug Targets, 2018, 20, 87-95.	2.1	34
16	Activity of Toscana and Rift Valley fever virus transcription complexes on heterologous templates. Journal of General Virology, 2001, 82, 781-785.	2.9	33
17	Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. Infectious Agents and Cancer, 2006, 1, 6.	2.6	30
18	Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes. Cancers, 2019, 11, 138.	3.7	30

#	Article	IF	Citations
19	Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells. Journal of Molecular Medicine, 2018, 96, 211-221.	3.9	29
20	In vivo antitumor effect of an intracellular singleâ€chain antibody fragment against the E7 oncoprotein of human papillomavirus 16. International Journal of Cancer, 2014, 134, 2742-2747.	5.1	27
21	Intracellular anti-E7 human antibodies in single-chain format inhibit proliferation of HPV16-positive cervical carcinoma cells. International Journal of Cancer, 2005, 116, 564-570.	5.1	26
22	Immobilized HIVâ€1 Tat protein promotes gene transfer via a transactivationâ€independent mechanism which requires binding of Tat to viral particles. Journal of Gene Medicine, 2009, 11, 955-965.	2.8	26
23	Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner. Aids, 2014, 28, 2189-2200.	2.2	24
24	DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors. Molecular Biotechnology, 2018, 60, 773-782.	2.4	24
25	Simultaneous CD8+ T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs. Vaccines, 2021, 9, 240.	4.4	20
26	HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET. Current Drug Targets, 2015, 17, 33-45.	2.1	19
27	The Intracellular Delivery Of Anti-HPV16 E7 scFvs Through Engineered Extracellular Vesicles Inhibits The Proliferation Of HPV-Infected Cells . International Journal of Nanomedicine, 2019, Volume 14, 8755-8768.	6.7	18
28	HIV-1 Nef Impairs Key Functional Activities in Human Macrophages through CD36 Downregulation. PLoS ONE, 2014, 9, e93699.	2.5	16
29	Human antibody response to Toscana virus glycoproteins expressed by recombinant baculovirus. Journal of Medical Virology, 2002, 68, 615-619.	5.0	13
30	The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells. Angiogenesis, 2014, 17, 831-838.	7.2	13
31	The CD8+ T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIXTM Adjuvant. Vaccines, 2016, 4, 42.	4.4	13
32	Trans-dissemination of exosomes from HIV-1-infected cells fosters both HIV-1 trans-infection in resting CD4+ T lymphocytes and reactivation of the HIV-1 reservoir. Archives of Virology, 2017, 162, 2565-2577.	2.1	11
33	Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases. Pharmaceutics, 2020, 12, 529.	4.5	11
34	Strong SARS-CoV-2 N-Specific CD8+ T Immunity Induced by Engineered Extracellular Vesicles Associates with Protection from Lethal Infection in Mice. Viruses, 2022, 14, 329.	3.3	11
35	N-Terminal Fatty Acids of NEFMUT Are Required for the CD8+ T-Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles. Vaccines, 2020, 8, 243.	4.4	8
36	Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors. Journal of Experimental and Clinical Cancer Research, 2021, 40, 37.	8.6	8

#	Article	IF	Citations
37	Clearance of Human Herpesvirus 8 from Blood and Regression of Leukopeniaâ€Associated Aggressive Classic Kaposiâ€™s Sarcoma during Interferonâ€Î± Therapy: A Case Report. Clinical Infectious Diseases, 2001, 33, 1782-1785.	5.8	7
38	KSHV G-protein coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase-2 expression mediates angiogenesis and tumorigenesis in Kaposiâ€™s sarcoma. PLoS Pathogens, 2020, 16, e1009006.	4.7	7
39	Extracellular vesicle-mediated intercellular communication in HIV-1 infection and its role in the reservoir maintenance. Cytokine and Growth Factor Reviews, 2020, 51, 40-48.	7.2	6
40	Long-Term Antitumor CD8+ T Cell Immunity Induced by Endogenously Engineered Extracellular Vesicles. Cancers, 2021, 13, 2263.	3.7	5
41	Targeting Human Papillomavirus-Associated Cancer by Oncoprotein-Specific Recombinant Antibodies. International Journal of Molecular Sciences, 2021, 22, 9143.	4.1	5
42	Primary Effusion Lymphoma Cells Undergoing Human Herpesvirus Type 8 Productive Infection Produce C-Type Retroviral Particles. International Journal of Immunopathology and Pharmacology, 2008, 21, 999-1006.	2.1	4
43	Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs. Journal of Molecular Medicine, 2019, 97, 1139-1153.	3.9	4
44	The C-Terminal Domain of Nefmut Is Dispensable for the CD8+ T Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles. Vaccines, 2021, 9, 373.	4.4	4
45	Activation of Anti-SARS-CoV-2 Human CTLs by Extracellular Vesicles Engineered with the N Viral Protein. Vaccines, 2022, 10, 1060.	4.4	4
46	Uncovering the role of defective HIV-1 in spreading viral infection. Future Virology, 2015, 10, 371-381.	1.8	1
47	In Vivo-Restricted and Reversible Malignancy Induced by Human Herpesvirus-8 KSHV: A Cell and Animal Model of Virally Induced Kaposi's Sarcoma. Cancer Cell, 2007, 11, 471.	16.8	0
48	Role of Extracellular Vesicles in Human Papillomavirus-Induced Tumorigenesis. , 2019, , .		0
49	Extracellular Vesicles and Their Use as Vehicles of Immunogens. Methods in Molecular Biology, 2022, 2504, 177-198.	0.9	0